IBRX Q4 2019 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$920,000+13042.9% YoY

Gross Profit

$920,000100.0% margin

Operating Income

-$21M-2239.0% margin

Net Income

-$22M-2421.3% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+7566.7%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$143M

Total Liabilities

$22M

Stockholders' Equity

$121M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$920,000	$7,000	+13042.9%
Gross Profit	$920,000	$7,000	+13042.9%
Operating Income	-$21M	-$17M	-18.9%
Net Income	-$22M	-$17M	-28.5%